Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Zoetis Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Return on Equity (ROE) since 2012
- Total Asset Turnover since 2012
- Price to Sales (P/S) since 2012
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Zoetis Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
- Gross Profit Margin
- The gross profit margin demonstrates a consistently high level, starting at approximately 68.18% in March 2020 and maintaining a steady range generally between 69% and 70%. There is a gradual increasing trend observed over the examined quarters, reaching just above 70% towards early 2024, indicating improved efficiency in production or favorable pricing strategies.
- Operating Profit Margin
- Operating profit margin shows a positive trajectory beginning from 31.42% in March 2020 and gradually increasing over time. The margin demonstrates resilience by stabilizing in the mid-30% range, peaking around 36.1% in early 2023, and maintaining this level around 35% to 36% thereafter. This suggests effective control of operating expenses relative to revenue, contributing to higher profitability.
- Net Profit Margin
- Net profit margin follows a similar upward trend, moving from just under 24% in early 2020 to above 27% by early 2024. The margin exhibits steady growth, indicating a favorable trend in overall profitability after accounting for all expenses, taxes, and other costs. This consistent increase reflects strong bottom-line performance.
- Return on Equity (ROE)
- Return on equity fluctuates notably within the period, initially increasing from around 55.39% in March 2020 to a peak exceeding 58% by mid-2020. However, it then declines and stabilizes around the low-to-mid 40 percentile range for the subsequent quarters. Starting in early 2023, a slight upward recovery is observed, stabilizing near 47% by early 2024. The variations suggest changes in financial leverage or net income impacting shareholder returns.
- Return on Assets (ROA)
- Return on assets shows a generally positive progression over the observed timeline. Beginning at approximately 13% in early 2020, it declines slightly before steadily increasing and reaching a peak of about 16.66% in March 2024. This upward trend indicates improved efficiency in utilizing assets to generate profits, reflecting operational strength and asset management improvements.
Return on Sales
Return on Investment
Gross Profit Margin
Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Gross profit | ||||||||||||||||||||||||||||
Revenue | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Gross profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2024 Calculation
Gross profit margin = 100
× (Gross profitQ1 2024
+ Gross profitQ4 2023
+ Gross profitQ3 2023
+ Gross profitQ2 2023)
÷ (RevenueQ1 2024
+ RevenueQ4 2023
+ RevenueQ3 2023
+ RevenueQ2 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue showed an overall upward trend from March 31, 2019 to March 31, 2024. Initially, revenues increased steadily each quarter, moving from $1,455 million in March 2019 to $1,674 million by December 2019. Following a slight dip during the first half of 2020, revenue recovered and continued to grow, reaching a peak of $2,213 million in September 2023. The data shows that despite minor fluctuations, revenue maintained a long-term growth trajectory, indicating consistent market demand and effective sales strategies.
- Gross Profit Analysis
- Gross profit exhibited a consistent increase throughout the analyzed period, with values rising from $937 million in March 2019 to a peak of $1,573 million in June 2023. The trend mirrors revenue growth, albeit with some short-term volatility. Notably, gross profit remained relatively stable in the 2022-2024 period, fluctuating between $1,395 million and $1,573 million, reflecting effective cost controls despite variable revenue levels.
- Gross Profit Margin Patterns
- Starting from the data availability point in March 2020, the gross profit margin consistently hovered around 69% to 70%. It fluctuated minimally from a low of 68.18% in March 2020 to a high of 70.56% in June 2022. This stability indicates disciplined operational cost management, allowing the company to maintain profitability relative to revenue across changing market conditions.
- Summary of Financial Health
- The combined revenue and gross profit trends suggest sustained growth and operational efficiency. Revenue growth outpaced early period dips, while gross profit margins remained stable, underscoring effective cost management and pricing strategies. The company's financial performance over the analyzed intervals demonstrates resilience and the capacity to generate consistent profit margins in a dynamic market environment.
Operating Profit Margin
Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Operating income | ||||||||||||||||||||||||||||
Revenue | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Operating profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2024 Calculation
Operating profit margin = 100
× (Operating incomeQ1 2024
+ Operating incomeQ4 2023
+ Operating incomeQ3 2023
+ Operating incomeQ2 2023)
÷ (RevenueQ1 2024
+ RevenueQ4 2023
+ RevenueQ3 2023
+ RevenueQ2 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The quarterly financial data over the analyzed period exhibits several noteworthy trends in operating income, revenue, and operating profit margin.
- Operating Income
- Operating income demonstrates a generally upward trajectory from the first quarter of 2019 through the first quarter of 2024, despite some fluctuations. Initial values started at 423 million USD in March 2019, climbing significantly, with notable peaks such as 787 million USD in March 2022 and 826 million USD in June 2023. There are however intermittent decreases, for example, from 719 million USD in September 2021 down to 592 million USD in December 2021, followed by recovery. This variability indicates some volatility but an overall positive growth pattern in operating income over the period.
- Revenue
- Revenue shows a consistent increase across the time frame, rising from 1,455 million USD in the first quarter of 2019 to 2,190 million USD in the first quarter of 2024. This growth is steady with minor short-term fluctuations. Notably, revenue surpassed the 2,000 million USD mark starting in 2022 and continued slightly upward through early 2024. This trend suggests strengthening sales and market demand or expansion over the period analyzed.
- Operating Profit Margin
- The operating profit margin, available from the fourth quarter of 2019 onward, reflects an improvement in profitability efficiency. Starting around 31.4%, it increased progressively to values generally exceeding 35% by 2020 and stabilizing around this higher level through 2024. The margin peaks vary slightly but maintain a range typically between 35% and 36%, indicating sustained operational efficiency and cost management contributing to maintaining profitability as revenues grow.
In summary, the data reveals steady revenue growth accompanied by an improving and stable operating profit margin, which collectively contribute to generally rising operating income figures. Some volatility in operating income is present but does not detract from the overall positive financial performance trend across the quarters.
Net Profit Margin
Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net income attributable to Zoetis Inc. | ||||||||||||||||||||||||||||
Revenue | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Net profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2024 Calculation
Net profit margin = 100
× (Net income attributable to Zoetis Inc.Q1 2024
+ Net income attributable to Zoetis Inc.Q4 2023
+ Net income attributable to Zoetis Inc.Q3 2023
+ Net income attributable to Zoetis Inc.Q2 2023)
÷ (RevenueQ1 2024
+ RevenueQ4 2023
+ RevenueQ3 2023
+ RevenueQ2 2023)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue shows a generally increasing trend over the analyzed periods from March 2019 through March 2024. Initial revenue of approximately 1,455 million USD in March 2019 grew steadily, reaching a peak of around 2,213 million USD by December 2023. Some quarters show slight dips or stabilization, such as a minor decline from December 2020 to March 2021 and fluctuations between 2022 and 2024, but the overall direction is upward, indicating sustained growth in sales.
- Net Income Patterns
- Net income attributable to the company displays variability across quarters but generally follows an upward trajectory aligned with revenue growth. Starting at 312 million USD in March 2019, net income increased significantly in several quarters, peaking notably at 671 million USD in June 2023. There are observable fluctuations, including declines in some quarters such as December 2019 and December 2020. Despite these fluctuations, net income maintains a positive increasing pattern up to the most recent data point of 599 million USD in March 2024.
- Net Profit Margin Analysis
- The net profit margin exhibits a consistent and gradual increase over the periods where data is available, beginning from approximately 23.96% in March 2020 and rising to approximately 27.38% by March 2024. This indicates improving profitability efficiency relative to revenue, as net income grows at a slightly faster pace than revenue. Margins remain quite stable quarter over quarter, fluctuating within a narrow range around the mid- to high-20 percent level, reflecting controlled cost management and operational effectiveness.
- Overall Financial Health Insights
- The company demonstrates steady revenue growth accompanied by rising net income and expanding profit margins, suggesting improved operational efficiency and effective cost control over the period analyzed. While some quarters experience temporary declines or stagnation, these are generally followed by recoveries and growth. The upward trend in net profit margin underscores an ability to enhance value creation from revenue streams.
Return on Equity (ROE)
Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net income attributable to Zoetis Inc. | ||||||||||||||||||||||||||||
Total Zoetis Inc. equity | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
ROE1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2024 Calculation
ROE = 100
× (Net income attributable to Zoetis Inc.Q1 2024
+ Net income attributable to Zoetis Inc.Q4 2023
+ Net income attributable to Zoetis Inc.Q3 2023
+ Net income attributable to Zoetis Inc.Q2 2023)
÷ Total Zoetis Inc. equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income Attributable to Zoetis Inc.
- The net income exhibits a generally upward trend over the observed periods, with some fluctuations. Starting at 312 million USD in the first quarter of 2019, it increased to a peak of 595 million USD by the first quarter of 2022. Thereafter, net income experienced some variability, decreasing to 461 million USD by the end of 2022 before recovering to 671 million USD by the third quarter of 2023. The most recent quarter shows a slight decline to 599 million USD. Overall, net income demonstrates substantial growth compared to the starting value, reflecting a positive earnings trajectory.
- Total Zoetis Inc. Equity
- Total equity shows consistent growth from 2.3 billion USD in March 2019 to approximately 5.1 billion USD by the first quarter of 2024. There is a steady rise in equity across the quarters, with minor periods of plateau or slight decline, notably towards the end of 2022 and the first half of 2023. Despite these minor dips, the equity base nearly doubled over the analyzed timeframe, indicating strengthening shareholder equity and possibly retained earnings accumulation.
- Return on Equity (ROE)
- ROE data is available from December 2019 onward and remains relatively stable with a slight downward trend early on before stabilizing. Initial ROE values are very high, exceeding 50% in late 2019 and early 2020, then decreasing to the low 40% range by late 2020 and through 2021. From 2022 onward, ROE fluctuates between approximately 44% and 48%, showing consistent shareholder returns relative to equity. This stable performance suggests effective management of equity to generate profit, despite fluctuations in net income and equity levels.
- Overall Analysis
- The data reflects a company with strong profitability improvements and equity growth over the five-year period. Net income's upward trend indicates successful operational or strategic initiatives, while the growth in equity implies reinvestment of earnings or capital inflows. The ROE, though high initially and then moderating, remains robust, signaling efficient use of equity resources. Temporary declines in net income and equity around late 2022 and early 2023 suggest possible external challenges or investments during those periods, but recovery thereafter sustains an overall positive financial health outlook.
Return on Assets (ROA)
Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net income attributable to Zoetis Inc. | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
ROA1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2024 Calculation
ROA = 100
× (Net income attributable to Zoetis Inc.Q1 2024
+ Net income attributable to Zoetis Inc.Q4 2023
+ Net income attributable to Zoetis Inc.Q3 2023
+ Net income attributable to Zoetis Inc.Q2 2023)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income attributable to Zoetis Inc.
- The net income shows a fluctuating but overall upward trend over the observed quarterly periods. From March 31, 2019, where it was recorded at $312 million, the net income generally increased with some quarters showing peaks and declines. Notably, there were significant surges during March 31, 2021 ($559 million) and June 30, 2023 ($671 million). The net income reached its highest point at June 30, 2023, before experiencing some moderation. The value at March 31, 2024 stands at $599 million, indicating that although there was a dip post mid-2023, profitability remains elevated compared to earlier periods.
- Total Assets
- Total assets exhibit a gradual and steady increase over the period. Starting from approximately $10.9 billion in March 31, 2019, assets grew to approximately $14.3 billion by March 31, 2024. There are minor fluctuations quarter over quarter, but the overall asset base shows consistent expansion, reflecting possible ongoing investments or acquisitions contributing to asset growth.
- Return on Assets (ROA)
- The return on assets shows a consistent positive trajectory, indicating improving efficiency in generating net income from the asset base. From around 13% in early 2020, ROA steadily increased over the years to reach about 16.7% by March 31, 2024. The increase in ROA, along with the rise in net income and asset base, suggests a more effective utilization of assets in creating shareholder value. The trend reflects strengthening profitability and operational efficiency despite the asset base expansion.
- Overall Insights
- The dataset reveals a company exhibiting solid financial growth, marked by increasing net income and assets. The upward trend in ROA reinforces that asset growth has been managed effectively, with improved profitability ratios. While some quarterly variations in net income exist, these have not disrupted the overall positive momentum. The increases suggest successful strategic implementations and market presence strengthening over these periods.